Literature DB >> 18396043

Late onset in dysferlinopathy widens the clinical spectrum.

L Klinge1, A F Dean, W Kress, P Dixon, R Charlton, J S Müller, L V Anderson, V Straub, R Barresi, H Lochmüller, K Bushby.   

Abstract

LGMD2B, Miyoshi Myopathy and Distal Anterior Compartment Myopathy are caused by mutations in the dysferlin gene (DYSF) leading to progressive muscular weakness and wasting with onset usually within the second or third decade of life. We here present a patient with disease onset at 73 years. The presenting symptom was exercise-induced stiffness of the trunk and proximal leg muscles without major progression over a period of 12 years. Gastrocnemius muscle biopsy revealed dystrophic morphology and biochemical depletion of dysferlin, while sequence analysis revealed compound heterozygous splicing mutations of the dysferlin gene. This case represents the eldest age of onset of dysferlinopathy reported so far and widens the clinical spectrum of this disease.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18396043     DOI: 10.1016/j.nmd.2008.01.004

Source DB:  PubMed          Journal:  Neuromuscul Disord        ISSN: 0960-8966            Impact factor:   4.296


  20 in total

Review 1.  Immunobiology of Inherited Muscular Dystrophies.

Authors:  James G Tidball; Steven S Welc; Michelle Wehling-Henricks
Journal:  Compr Physiol       Date:  2018-09-14       Impact factor: 9.090

2.  Identification of a Novel Mutation in the Titin Gene in a Chinese Family with Limb-Girdle Muscular Dystrophy 2J.

Authors:  Wen Zheng; Han Chen; Xiong Deng; Lamei Yuan; Yan Yang; Zhi Song; Zhijian Yang; Yuan Wu; Hao Deng
Journal:  Mol Neurobiol       Date:  2015-09-21       Impact factor: 5.590

3.  Effect of Ibuprofen on Skeletal Muscle of Dysferlin-Null Mice.

Authors:  Alyssa F Collier; Jessica Gumerson; Kimmo Lehtimäki; Jukka Puoliväli; Jace W Jones; Maureen A Kane; Sankeerth Manne; Andrea O'Neill; Hillarie P Windish; Toni Ahtoniemi; Bradley A Williams; Douglas E Albrecht; Robert J Bloch
Journal:  J Pharmacol Exp Ther       Date:  2017-12-28       Impact factor: 4.030

4.  Genetic ablation of complement C3 attenuates muscle pathology in dysferlin-deficient mice.

Authors:  Renzhi Han; Ellie M Frett; Jennifer R Levy; Erik P Rader; John D Lueck; Dimple Bansal; Steven A Moore; Rainer Ng; Daniel Beltrán-Valero de Bernabé; John A Faulkner; Kevin P Campbell
Journal:  J Clin Invest       Date:  2010-11-08       Impact factor: 14.808

5.  1α,25(OH)(2)-Vitamin D3 increases dysferlin expression in vitro and in a human clinical trial.

Authors:  Noemi De Luna; Jordi Díaz-Manera; Carmen Paradas; Cristina Iturriaga; Ricardo Rojas-García; Josefa Araque; Mireia Genebriera; Ignasi Gich; Isabel Illa; Eduard Gallardo
Journal:  Mol Ther       Date:  2012-08-21       Impact factor: 11.454

6.  A founder mutation in Anoctamin 5 is a major cause of limb-girdle muscular dystrophy.

Authors:  Debbie Hicks; Anna Sarkozy; Nuria Muelas; Katrin Köehler; Angela Huebner; Gavin Hudson; Patrick F Chinnery; Rita Barresi; Michelle Eagle; Tuomo Polvikoski; Geraldine Bailey; James Miller; Aleksander Radunovic; Paul J Hughes; Richard Roberts; Sabine Krause; Maggie C Walter; Steven H Laval; Volker Straub; Hanns Lochmüller; Kate Bushby
Journal:  Brain       Date:  2011-01       Impact factor: 13.501

7.  Homologous recombination mediates functional recovery of dysferlin deficiency following AAV5 gene transfer.

Authors:  William E Grose; K Reed Clark; Danielle Griffin; Vinod Malik; Kimberly M Shontz; Chrystal L Montgomery; Sarah Lewis; Robert H Brown; Paul M L Janssen; Jerry R Mendell; Louise R Rodino-Klapac
Journal:  PLoS One       Date:  2012-06-15       Impact factor: 3.240

8.  Comparison of dysferlin expression in human skeletal muscle with that in monocytes for the diagnosis of dysferlin myopathy.

Authors:  Eduard Gallardo; Noemi de Luna; Jordi Diaz-Manera; Ricardo Rojas-García; Lidia Gonzalez-Quereda; Bàrbara Flix; Antoine de Morrée; Silvère van der Maarel; Isabel Illa
Journal:  PLoS One       Date:  2011-12-16       Impact factor: 3.240

9.  New aspects on patients affected by dysferlin deficient muscular dystrophy.

Authors:  Lars Klinge; Ahmed Aboumousa; Michelle Eagle; Judith Hudson; Anna Sarkozy; Gianluca Vita; Richard Charlton; Mark Roberts; Volker Straub; Rita Barresi; Hanns Lochmüller; Kate Bushby
Journal:  J Neurol Neurosurg Psychiatry       Date:  2009-06-14       Impact factor: 10.154

10.  Clinical features and a mutation with late onset of limb girdle muscular dystrophy 2B.

Authors:  Toshiaki Takahashi; Masashi Aoki; Naoki Suzuki; Maki Tateyama; Chikako Yaginuma; Hitomi Sato; Miho Hayasaka; Hitomi Sugawara; Mariko Ito; Emi Abe-Kondo; Naoko Shimakura; Tohru Ibi; Satoshi Kuru; Tadashi Wakayama; Gen Sobue; Naoki Fujii; Toshio Saito; Tsuyoshi Matsumura; Itaru Funakawa; Eiichiro Mukai; Toru Kawanami; Mitsuya Morita; Mineo Yamazaki; Takashi Hasegawa; Jun Shimizu; Shoji Tsuji; Shigeki Kuzuhara; Hiroyasu Tanaka; Masaru Yoshioka; Hidehiko Konno; Hiroshi Onodera; Yasuto Itoyama
Journal:  J Neurol Neurosurg Psychiatry       Date:  2012-12-15       Impact factor: 10.154

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.